Potential Analysis of Drug Interactions in  Schizophrenia Cases At One of the Bandung District Pharmacy, Indonesia

Yane Srie Herliany; Hari Nurdin

doi:10.47194/ijgor.v5i1.291

Authors

Yane Srie Herliany
yane.srie.h@gmail.com
Bachelor Program of Pharmacy, Bumi Siliwangi Academy of Pharmacy, Bandung, West Java, Indonesia Jl.Rancabolang No.104 Margahayu Raya, Bandung 40286, Indonesia
Hari Nurdin Bachelor Program of Pharmacy, Bumi Siliwangi Academy of Pharmacy, Bandung, West Java, Indonesia Jl.Rancabolang No.104 Margahayu Raya, Bandung 40286, Indonesia

Keywords:

Schizophrenia, drug interactions, pharmacodynamics, pharmacokinetics, polypharmacy

Abstract

Schizophrenia is a heterogeneous syndrome of thought disturbances, delusions, hallucinations, emotional disturbances, decreased cognitive function and disturbed psychosocial functions. Treatment of schizophrenia aims to prevent hospitalization, ensure the patient's symptoms are stable and independent such as work or school. The purpose of this study was to determine the potential for drug interactions in schizophrenia cases based on their mechanism of action and severity. This research method is a descriptive study using data collected retrospectively on prescription drug data sheets in the pharmacy. The collected data were analyzed quantitatively and qualitatively. The results of the study from a total of 133 prescriptions found potential drug interactions in 509 cases. Drug interactions based on the mechanism of action, pharmacodynamics were found in 494 cases and 15 cases of pharmacokinetic . Based on the level of severity, there were interactions with 15 cases of mild severity, 287 cases of moderate severity and 217 cases of severe severity

References

Ayani, N., Morimoto, T., Sakuma, M., Kikuchi, T., Watanabe, K., & Narumoto, J. (2021). Antipsychotic polypharmacy is associated with adverse drug events in psychiatric inpatients: the Japan Adverse Drug Events study. Journal of clinical psychopharmacology, 41(4), 397.

Baxter, K., & Preston, C. L. (Eds.). (2010). Stockley's drug interactions (Vol. 495). London: Pharmaceutical Press.

Dwi Aulia, R., Sri Adi, S., Melisa Intan, B., Dika Pramita, D., & Ice Laila, N. (2018). Potensi Interaksi Obat pada Pasien Skizofrenia di Salah Satu Rumah Sakit Jiwa di Provinsi Jawa Barat. Potensi Interaksi Obat pada Pasien Skizofrenia di Salah Satu Rumah Sakit Jiwa di Provinsi Jawa Barat, 7(4), 280-293.

Dyer, S. M., Harrison, S. L., Laver, K., Whitehead, C., & Crotty, M. (2018). An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. International psychogeriatrics, 30(3), 295-309.

Farooq, S., Tunmore, J., & Comber, R. (2021). Pharmacological or non-pharmacological interventions for treatment of common mental disorders associated with Tuberculosis: A systematic review. Chronic Respiratory Disease, 18, 14799731211003937.

Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018). Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophrenia Bulletin, 44(3), 603-619.

Krishnakumar, S., & Kethar, J. (2023). Efficacy of virtual reality treatment with NIBS for Schizophrenia. Journal of Student Research, 12(1).

Ri, K (2013). Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS) 2018. Laporan Nasional 2013. 2018: 1â€“384.

Shah, T. D., & Prabhu, S. (2020). Correlation between Physical Activity and Quality of Life in Schizophrenic Patients. Journal of Exercise Science & Physiotherapy Vol, 16(2).

Wahyudi, A., & Fibriana, A. I. (2016). Faktor resiko terjadinya Skizofrenia (studi kasus di Wilayah Kerja Puskesmas Pati II). Public Health Perspective Journal, 1(1).